BRIEF published on 10/10/2024 at 08:32, 1 year 1 month ago AB Science Reports Mid-2024 Financial Results and Clinical Developments Financial Results Clinical Trials Capital Increase AB Science Masitinib
BRIEF published on 10/10/2024 at 08:32, 1 year 1 month ago AB Science publie ses résultats financiers et ses développements cliniques pour la mi-2024 Résultats Financiers Augmentation De Capital Essais Cliniques Masitinib Sciences AB
PRESS RELEASE published on 10/10/2024 at 08:27, 1 year 1 month ago AB Science: Revenues for the first half of 2024 and update on AB Science’s activities AB Science presents financial results for the first half of 2024, updates on clinical development in ALS and MS, positive results in Covid-19 study, and intellectual property strengthening. AB announces capital increase and coverage initiations. Press Release by AB Science SA Financial Results Capital Increase Clinical Development Intellectual Property AB Science
PRESS RELEASE published on 10/10/2024 at 08:27, 1 year 1 month ago AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science AB Science présente ses résultats financiers au premier semestre 2024 et les événements clés de la période, incluant le développement du masitinib, les résultats positifs dans la Covid-19 et le renforcement de la propriété intellectuelle Résultats Financiers COVID-19 Développement Clinique AB Science Masitinib
BRIEF published on 09/30/2024 at 08:34, 1 year 2 months ago AB Science annonce une augmentation de capital de 5,0 millions d’euros Augmentation De Capital Développement Clinique AB Science Masitinib Investisseurs Européens
BRIEF published on 09/30/2024 at 08:34, 1 year 2 months ago AB Science announces a capital increase of 5.0 million euros Capital Increase Clinical Development AB Science Masitinib European Investors
PRESS RELEASE published on 09/30/2024 at 08:29, 1 year 2 months ago AB Science annonce une augmentation de capital de 5,0 millions d’euros AB Science annonce avec succès une augmentation de capital de 5 millions d’euros par placement privé pour financer le développement clinique de AB8939 Placement Privé Augmentation De Capital Développement Clinique AB Science AB8939
BRIEF published on 09/23/2024 at 17:56, 1 year 2 months ago AB Science fait le point sur le développement du masitinib dans les formes progressives de sclérose en plaques Sclérose En Plaques Traitement Masitinib ECTRIMS 2024 Neurodégénératif
Published on 12/05/2025 at 17:15, 19 minutes ago TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 34 minutes ago Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 1 hour 34 minutes ago SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 1 hour 49 minutes ago Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme
Published on 12/05/2025 at 15:45, 1 hour 49 minutes ago Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 17:00, 34 minutes ago EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 9 minutes ago 4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 24 minutes ago Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 1 hour 34 minutes ago EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 1 hour 34 minutes ago EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 17:18, 16 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 16 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 2 hours 23 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 2 hours 23 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 3 hours 35 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE